The Australian Competition and Consumer Commission has signed off on pharmaceutical giant GlaxoSmithKline’s proposed acquisition of fellow heavyweight Pfizer, a merger which will put pain medications Panadol, Voltaren and Advil all under one roof, with the competition cop saying Nurofen maker Reckitt will still be able to compete.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

For information on rights and reprints, contact subscriptions@lawyerly.com.au